Bone Metastases in Patients with Pancreatic NETs: Prevalence and Prognosis
Hormone and Metabolic Research · 01.12.2023 · 55 (12) · 827-834
DOI: 10.1055/a-2159-5548 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hormone and Metabolic Research, erschienen am 01.12.2023. Verfasst von Annie Mathew und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Diabetes and Metabolism and Division of Laboratory Research, University Hospital Essen, Essen, Germany. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Bone Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
The clinical relevance of bone metastases (BM) in advanced pancreatic neuroendocrine tumors (PanNETs) is poorly described. We analyzed 314 consecutive PanNET patients treated at the European Neuroendocrine Tumour Society (ENETS) Center Essen between 2009 and 2021 in terms of the occurrence and clinical and prognostic impact of BM using hybrid imaging with 68Ga-DOTATOC PET/CT. According to UICC staging, 171/314 (54.5%) patients had stage IV PanNETs. BM was diagnosed in 62/171 (36.3%) patients. Initially, 35% of BMs were visible by pathological tracer uptake only. Skeletal-related events (SREs) were detected in 11 of the 62 patients (17.7%). Patients with antiresorptive therapy had a significantly lower rate of SRE (2/36, 5.6%) than individuals without bone-specific therapy (9/26, 34.6%) (odds ratio 9.0, p=0.0054, Fisher’s exact test). The median overall survival (OS) was 82 months (53.6–110.4, 95% CI) in the stage IV PanNET cohort. The median OS was significantly lower for patients with BM (63 months; 49.9–76.0, 95% CI) than for patients with distant metastases other than BM (116 months; 87.6–144.3, 95% CI) (p=0.016, log-rank test). BM occurs in more than one-third of advanced PanNETs and is associated with an unfavorable prognosis. One in five patients experiences a persistent quality-of-life-lowering SRE. Antiresorptive therapy is associated with a more favorable risk of SREs and should be offered to all patients with BM in PanNETs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Endocrinology, Diabetes and Metabolism and Division of Laboratory Research, University Hospital Essen, Essen, Germany.
- Department of Nuclear Medicine, University Hospital Essen, Essen, Germany.
- Institute for Diagnostics and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
Zitieren
APA
Mathew, A., Fendler, W. P., Theysohn, J., Herrmann, K., Führer, D., & Lahner, H. (2023). Bone Metastases in Patients with Pancreatic NETs: Prevalence and Prognosis. Hormone and Metabolic Research, 55(12), 827-834. https://doi.org/10.1055/a-2159-5548
Vancouver
Mathew A, Fendler WP, Theysohn J, Herrmann K, Führer D, Lahner H. Bone Metastases in Patients with Pancreatic NETs: Prevalence and Prognosis. Hormone and Metabolic Research. 2023;55(12):827-834. doi:10.1055/a-2159-5548
BibTeX
@article{Mathew2023,
author = {Mathew, Annie and Fendler, Wolfgang P and Theysohn, Jens and Herrmann, Ken and Führer, Dagmar and Lahner, Harald},
title = {Bone Metastases in Patients with Pancreatic NETs: Prevalence and Prognosis},
journal = {Hormone and Metabolic Research},
year = {2023},
volume = {55},
number = {12},
pages = {827--834},
doi = {10.1055/a-2159-5548}
}
EUVIMED